Ansun Biopharma Stock

ansunbiopharma.comBioTechFounded: 2003Funding to Date: $189.78MM

Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics.

Register for Details

For more details on financing and valuation for Ansun Biopharma, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Nancy Chang Ph.D
Chief Executive Officer & Chairperson of the Board
George Wang
Chief Technology Officer
Mikael Havluciyan
Chief Legal Officer & Corporate Secretary
Ivy Fan
Executive
Stanley Lewis MD
Chief Medical Officer

Board Members

Aimin Wu
Sinopharm Healthcare Fund
Allen Chao Ph.D
Dave Chenn
Donald Payne
Karen Liu Ph.D
Michael Chang Ph.D
Michael Chao MD
Nancy Chang Ph.D
Yi Shi Ph.D
Lilly Asia Ventures

Other companies like Ansun Biopharma in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Ansun aims to drive the global Phase 3 clinical trial of its experimental anti-viral medication.